Ipamorelin CJC 1295 Peptide: What the Research Shows

Ipamorelin CJC 1295 peptide is a research-only stack of two growth hormone secretagogues: ipamorelin, a selective ghrelin receptor agonist, and CJC-1295, a long-acting GHRH analog. The pair is studied together because each one activates a different receptor, which may produce a broader GH pulse than either peptide alone. Neither peptide is FDA-approved for human use in the United States, and both are sold for laboratory research only.

What Is the Ipamorelin CJC 1295 Peptide Stack?

When people search for what is cjc-1295 ipamorelin, they usually mean a blended research vial that contains both peptides in a fixed ratio. The most common ratio discussed is 1:1, though suppliers also sell 100 mcg of ipamorelin with 100 mcg of CJC-1295 (no DAC) in a single lyophilized powder.

Ipamorelin is a five-amino-acid peptide that mimics ghrelin at the GHS-R1a receptor. Animal studies describe it as one of the most selective GH secretagogues, with minimal effect on cortisol, prolactin, or appetite compared with older ghrelin mimetics.

CJC-1295 is a modified GRF(1-29) with a drug affinity complex that binds albumin and extends its half-life from minutes to several days. The version without that complex is often sold as mod GRF(1-29) and behaves more like natural GHRH.

The blend is frequently listed as cjc 1295 with ipamorelin peptide on vendor catalogs, and it remains one of the most requested GH-related research combinations.

How the Two Peptides Work Together

Growth hormone release is governed by two opposing signals: GHRH, which stimulates it, and somatostatin, which shuts it down. Hitting only one side of that system produces a limited pulse.

• Ipamorelin triggers GH release through the ghrelin receptor and also dampens somatostatin signaling, which is why it is often described as a pulse amplifier.
• CJC-1295 binds the GHRH receptor and keeps that stimulatory signal active for longer than native GHRH would.
• The combination activates two distinct receptors, so researchers describe the effect as synergistic rather than simply additive.

That gap in half-life is the main reason protocol designers pair the two instead of running either one alone.

Reported Dosing and Timing in Research

There is no FDA-approved dose of ipamorelin or CJC-1295 for humans, and published human data are thin. Most of what circulates online comes from small pilot studies, self-reported logs, and animal work.

Questions about the best time to take cjc 1295 ipamorelin usually come down to one idea: dosing when natural GH secretion is already high. Most protocols describe a single subcutaneous injection at night, before sleep, because the largest natural GH pulse occurs during early deep sleep.

• Commonly cited ipamorelin amounts range from 100 to 300 mcg per injection.
• Commonly cited CJC-1295 (no DAC) amounts range from 100 to 200 mcg per injection.
• DAC versions of CJC-1295 are usually discussed as once or twice weekly because of the long half-life.
• Some protocols split dosing into morning and pre-sleep, although evidence for the split schedule is anecdotal.

These figures are research context, not a recommendation. Anyone considering a growth hormone secretagogue should speak with a licensed healthcare professional first.

How the Stack Compares With Other Options

Inside the peptide research community, the question of cjc-1295 ipamorelin vs tesamorelin comes up often. Tesamorelin is the only GHRH analog approved by the FDA, and its approval is limited to HIV-associated lipodystrophy rather than general fat loss or performance.

Other compounds are sometimes discussed alongside the base stack, each with a different research target.

Bodybuilding forums often frame the blend as a cjc 1295 ipamorelin muscle growth protocol, but no controlled human trial has measured lean mass gains from the combination. Claims about fat loss and recovery are similarly extrapolated from mechanism rather than proven outcomes.

Adding AOD-9604 or IGF-1 LR3 to the base stack changes the research question from how much GH is released to what happens downstream, and stacking multiple GH secretagogues raises the risk of overlapping effects.

Side Effects, Safety, and Legal Status

Reported side effects in self-experimentation logs include injection-site irritation, water retention, joint stiffness, headache, and fatigue. Because these peptides are not approved for human use, no manufacturer has completed the safety studies needed to establish a reliable risk profile.

CJC-1295 with DAC has a long half-life, which means a reaction cannot be resolved quickly the way it can with a short-acting peptide. That is one reason many researchers prefer the non-DAC version for early work.

In the United States, ipamorelin and CJC-1295 are not approved for human use and cannot lawfully be sold as dietary supplements or prescription drugs. Products are labeled for research use only, and buying them for personal injection sits in a legal gray area.

Anyone with a pituitary condition, a history of cancer, or diabetes should avoid GH-related peptides without direct medical supervision.

Bottom Line

Ipamorelin CJC 1295 peptide is a two-receptor GH stack, not a single drug. The science behind each peptide is real, the human evidence for the combination is limited, and the blend is not FDA-approved for human use.